Part,  Chapter, Paragraph

 1   II,     5.  3.  5|      category includes all malignant tumours except non-melanoma skin
 2   II,     5.  3.  7|        treatment of several specific tumours in some nations, but still
 3   II,     5.  5.  3|          abnormalities such as brain tumours, genetic, metabolic or degenerative
 4   II,     5. 11.  3|          Some of the most aggressive tumours arise in the skin: melanoma,
 5   II,     5. 11.  3|          skin lymphomas, Merkel cell tumours and others (See Chapter
 6   II,     5. 11.  4|          cancers such as Merkel cell tumours, malignant fibrous histiocytomas,
 7   II,     5. 15.  3|           included in the list. Rare tumours, for instance, are excluded,
 8  III,    10.  2.  5|        susceptibility for developing tumours in later life. Endocrine
 9  III,    10.  3.  1| neurodegenerative diseases and brain tumours, the link to ELF fields
10  III,    10.  3.  1|             increased risk for brain tumours in long-term users, with
11  III,    10.  3.  1|          development of transplanted tumours. The open questions include
12  III,    10.  3.  2|        susceptibility for developing tumours in later life. Endocrine
13  III,    10.  4.  2|      hepatitis) Liver~abnormalities, tumours~genotoxic carcinogen~ ~EU
14  III,    10.  4.  2|             damage and~urinary tract tumours~(‘Balkan endemic~nephropathy’);~
15  Key,   Ap5.  0.  0|        tuberculosis~tularemia~tumour~tumours~turbinate~Turkey~typhi~typhoid~